| HEIDELBERG PHARMA AG O.N. |
| Deutschland |
| Gesundheit |
| DE000A11QVV0 / A11QVV |
| HPHA (Frankfurt) |
| FRA:HPHA, ETR:HPHA, HPHA:GR |
| - |
| https://heidelberg-pharma.. |
|
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in oncology, developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies. Its primary focus is on creating novel drugs that combine the specificit..
>Volltext.. |
| 130.57 Mio. EUR |
| 116.81 Mio. EUR |
| 1.44 Mio. EUR |
| -41.94 Mio. EUR |
| -41.83 Mio. EUR |
| -0.9 EUR |
| 1.15 Mio. EUR |
| 14.82 Mio. EUR |
| -31.27 Mio. EUR |
| 1.34 |
| -78.72% |
| -118.15% |
| - |
| - |
| - |
| - |
| HEIDELBERG PHARMA, WILEX |
| 26.04.26 |
|
||||
|
||||
|
||||
|
||||
|